var data={"title":"Raxibacumab (United States: Availability limited to CDC distribution from strategic national stockpile in consultation with local health department) : Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Raxibacumab (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department) : Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/532190?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-patient-drug-information\" class=\"drug drug_patient\">see &quot;Raxibacumab (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department) : Patient drug information&quot;</a> and <a href=\"topic.htm?path=raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Raxibacumab (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department) : Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15826184\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote;</li>\n      <li>\n        Monoclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16235240\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Anthrax, prophylaxis or treatment:</b>   IV: 40 mg/kg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Administer diphenhydramine 25-50 mg (may administer oral or IV depending on the proximity to start of raxibacumab infusion) &le;1 hour prior to administration of raxibacumab to reduce the risk of infusion reactions.  Must be administered in combination with antimicrobial therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50989956\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer's labeling. However, dosage adjustment unlikely as clearance is nonrenal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987274\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16235239\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Raxibacumab (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department) : Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Anthrax, prophylaxis or treatment:</b> Children and Adolescents: IV: <b>Note:</b> Administer diphenhydramine (may administer oral or IV depending on the proximity to start of raxibacumab infusion) &le;1 hour prior to administration of raxibacumab to reduce the risk of infusion reactions.  Must be administered in combination with antimicrobial therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&le;15 kg: 80 mg/kg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;15 kg to 50 kg: 60 mg/kg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;50 kg: 40 mg/kg as a single dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51159761\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling; however, dosage adjustment unlikely as clearance is nonrenal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51159762\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustment provided in manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16235241\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16243478\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, solution: 50 mg/mL (34 mL) [contains polysorbate 80, sucrose 10 mg/mL]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16234640\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16234633\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Raxibacumab is not available for general public use. All supplies are currently owned by the federal government for inclusion in the Strategic National Stockpile and for use by the U.S. military. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16235258\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Premedicate with diphenhydramine &le;1 hour prior to raxibacumab infusion. Administer over 2 hours and 15 minutes; administration rate should be slower over the first 20 minutes to monitor for adverse reactions; slow or interrupt infusion if adverse reactions (including infusion-related reactions) occur.  Administer as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight: &le;1 kg: Infuse at 0.5 mL/hour for 20 minutes; increase rate to 3.5 mL/hour for the remaining infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight 1.1 to 2 kg: Infuse at 1 mL/hour for 20 minutes; increase rate to 7 mL/hour for the remaining infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight 2.1 to 3 kg: Infuse at 1.2 mL/hour for 20 minutes; increase rate to 10 mL/hour for the remaining infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight 3.1 to 4.9 kg: Infuse at 1.5 mL/hour for 20 minutes; increase rate to 12 mL/hour for the remaining infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight 5 to 10 kg: Infuse at 3 mL/hour for 20 minutes; increase rate to 25 mL/hour for the remaining infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight 11 to 30 kg: Infuse at 6 mL/hour for 20 minutes; increase rate to 50 mL/hour for the remaining infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight &ge;31 kg: Infuse at 15 mL/hour for 20 minutes; increase rate to 125 mL/hour for the remaining infusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15826186\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of inhalational anthrax  following exposure to <i>Bacillus anthracis</i> in combination with appropriate antimicrobial therapy; prophylaxis of inhalational anthrax when alternative therapies are unavailable or not appropriate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16235178\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Dermatologic: Skin rash (infusion-related; without diphenhydramine premedication: 22%; with diphenhydramine premedication: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">2% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;2%, postmarketing, and/or case reports: Anemia, back pain, drowsiness, fatigue, flushing, hypertension, increased creatine phosphokinase, increased serum amylase, insomnia, leukopenia, lymphadenopathy, muscle spasm, pain (at infusion site), palpitations, peripheral edema, prolonged prothrombin time, vasodepressor syncope, vertigo</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16234682\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16234683\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Infusion-related reactions (eg, rash, urticaria, pruritus) have been reported.  Premedication with diphenhydramine is recommended to reduce the risk. The administration rate is slowed over the first 20 minutes to monitor for adverse reactions; decrease the infusion rate or stop the infusion if adverse reactions (including infusion-related reactions) occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens).  Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Anthrax prophylaxis and treatment: Raxibacumab is not an antimicrobial agent; use should always be in combination with appropriate antimicrobial therapy.  Raxibacumab does not cross the blood brain barrier and is not appropriate for the prevention or treatment of meningitis due to anthrax infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Efficacy: The efficacy of raxibacumab in humans is presumptive and based solely on efficacy studies in animals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16369099\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16369097\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=87468&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16234656\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16234660\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. In general, guidelines for the prophylaxis and treatment of inhalational anthrax following exposure to <i>Bacillus anthracis</i> in pregnant and postpartum women are the same as nonpregnant adults (Meaney-Delman 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16234679\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if raxibacumab is excreted in breast milk. Immunoglobulins are excreted in breast milk, and although substantial absorption following consumption from breast milk is not expected, the potential effects are not known. In general, guidelines for the prophylaxis and treatment of inhalational anthrax following exposure to <i>Bacillus anthracis</i> in lactating women are the same as nonpregnant adults (Meaney-Delman 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16235221\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Raxibacumab is a recombinant human IgG1 lambda monoclonal antibody which binds and neutralizes free protective antigen (PA) component of <i>Bacillus anthracis</i> toxin; as a result, PA-mediated delivery of lethal toxin and edema toxin via the anthrax toxin receptor (ATR) into host cells of anthrax-infected individuals is inhibited.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16235223\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 0.07 L/kg (Migone 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: 20.44 &plusmn; 6.46  days (Migone 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Nonrenal (Migone 2009)</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mazumdar S, &ldquo;Raxibacumab,&rdquo; <i>MAbs</i>, 2009, 1(6):531-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/20068396/pubmed\" target=\"_blank\" id=\"20068396\">20068396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meaney-Delman D, Zotti ME, Creanga AA, et al; Workgroup on Anthrax in Pregnant and Postpartum Women. Special considerations for treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2). doi: 10.3201/eid2002.130611.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/24457117/pubmed\" target=\"_blank\" id=\"24457117\">24457117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Migone TS, Subramanian GM, Zhong J, et al, &ldquo;Raxibacumab for the Treatment of Inhalational Anthrax,&rdquo; <i>N Engl J Med</i>, 2009, 361(12):135-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/19587338/pubmed\" target=\"_blank\" id=\"19587338\">19587338</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raxibacumab [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 87468 Version 53.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F15826184\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F16235240\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50989956\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987274\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F16235239\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51159761\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51159762\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F16235241\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F16243478\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F16234640\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F16234633\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F16235258\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F15826186\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F16235178\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F16234682\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F16234683\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F16369099\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F16369097\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F16234656\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F16234660\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16234679\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F16235221\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F16235223\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/87468|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-patient-drug-information\" class=\"drug drug_patient\">Raxibacumab (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department) : Patient drug information</a></li><li><a href=\"topic.htm?path=raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information\" class=\"drug drug_pediatric\">Raxibacumab (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department) : Pediatric drug information</a></li></ul></div></div>","javascript":null}